|
Jan 3
|
Pharma Stock Roundup: PFE Ends Hemophilia Deal With SGMO & More
|
|
Jan 3
|
Positive data could expand use of Novartis’ gene therapy for SMA
|
|
Dec 31
|
Novartis' Gene Therapy Meets Primary Endpoint in SMA Study
|
|
Dec 31
|
Here's Why Novartis (NVS) is a Strong Growth Stock
|
|
Dec 31
|
Novartis’ Gene Therapy Shows Promise in Treating SMA
|
|
Dec 31
|
Novartis’ Phase III spinal muscular atrophy therapy trial meets primary endpoint
|
|
Dec 30
|
Novartis intrathecal onasemnogene abeparvovec Phase III study meets primary endpoint in children and young adults with SMA
|
|
Oct 5
|
Novartis AG (NVS): Driving Long-Term Growth with Strong Pipeline and Innovative Products
|
|
Oct 2
|
Here's Why You Should Add ALNY Stock to Your Portfolio Right Now
|
|
Oct 1
|
US HHS Reveal Cost Savings For 54 Prescription Drugs Including Novartis' Cancer Drug, Ozempic Could be Next
|
|
Sep 30
|
Top Research Reports for Apple, Tesla & T-Mobile US
|
|
Sep 30
|
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
|
|
Sep 27
|
Volkswagen, Novartis could surprise in Q3 earnings season, UBS analysts warn
|
|
Sep 25
|
Generate:Biomedicines and Novartis link on protein therapeutics development
|
|
Sep 24
|
Metsera touts long-acting GLP-1 drug; Novartis strikes an AI deal
|
|
Aug 29
|
Novartis teams up with Lindy Biosciences to improve biologic delivery
|
|
Aug 29
|
Novartis' Cholesterol Drug Meets Primary Goals in Late-Stage Study
|
|
Aug 29
|
Novartis’ Phase III trial of Leqvio in ASCVD patients meets primary endpoints
|
|
Aug 28
|
Novartis AG (NVS): A Cheap Pharmaceutical Stock to Buy According to Short Sellers
|
|
Aug 28
|
Novartis' Cholesterol-Lowering Drug Shows Encouraging Outcome In Late-Stage Study
|